These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12527704)

  • 1. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
    Rodrigues AD; Halpin RA; Geer LA; Cui D; Woolf EJ; Matthews CZ; Gottesdiener KM; Larson PJ; Lasseter KC; Agrawal NG
    Drug Metab Dispos; 2003 Feb; 31(2):224-32. PubMed ID: 12527704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
    Agrawal NG; Porras AG; Matthews CZ; Woolf EJ; Miller JL; Mukhopadhyay S; Neu DC; Gottesdiener KM
    J Clin Pharmacol; 2001 Oct; 41(10):1106-10. PubMed ID: 11583479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
    Agrawal NG; Porras AG; Matthews CZ; Rose MJ; Woolf EJ; Musser BJ; Dynder AL; Mazina KE; Lasseter KC; Hunt TL; Schwartz JI; McCrea JB; Gottesdiener KM
    J Clin Pharmacol; 2003 Mar; 43(3):268-76. PubMed ID: 12638395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
    Chauret N; Yergey JA; Brideau C; Friesen RW; Mancini J; Riendeau D; Silva J; Styhler A; Trimble LA; Nicoll-Griffith DA
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1059-62. PubMed ID: 11327589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
    Yuan JJ; Yang DC; Zhang JY; Bible R; Karim A; Findlay JW
    Drug Metab Dispos; 2002 Sep; 30(9):1013-21. PubMed ID: 12167567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.
    Kassahun K; McIntosh IS; Shou M; Walsh DJ; Rodeheffer C; Slaughter DE; Geer LA; Halpin RA; Agrawal N; Rodrigues AD
    Drug Metab Dispos; 2001 Jun; 29(6):813-20. PubMed ID: 11353749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
    Halpin RA; Porras AG; Geer LA; Davis MR; Cui D; Doss GA; Woolf E; Musson D; Matthews C; Mazenko R; Schwartz JI; Lasseter KC; Vyas KP; Baillie TA
    Drug Metab Dispos; 2002 Jun; 30(6):684-93. PubMed ID: 12019196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS.
    Rose MJ; Agrawal N; Woolf EJ; Matuszewski BK
    J Pharm Sci; 2002 Feb; 91(2):405-16. PubMed ID: 11835200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.
    Birbara CA; Puopolo AD; Munoz DR; Sheldon EA; Mangione A; Bohidar NR; Geba GP;
    J Pain; 2003 Aug; 4(6):307-15. PubMed ID: 14622687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
    Dallob A; Hawkey CJ; Greenberg H; Wight N; De Schepper P; Waldman S; Wong P; DeTora L; Gertz B; Agrawal N; Wagner J; Gottesdiener K
    J Clin Pharmacol; 2003 Jun; 43(6):573-85. PubMed ID: 12817520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, absorption, metabolism, and excretion of [
    Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
    Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
    Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and Pharmacokinetics of Etoricoxib in Thoroughbred Horses.
    Subhahar MB; Singh J; Albert PH; Kadry AM
    J Equine Vet Sci; 2020 May; 88():102942. PubMed ID: 32303303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity.
    Tacconelli S; Capone ML; Sciulli MG; Ricciotti E; Patrignani P
    Curr Med Res Opin; 2002; 18(8):503-11. PubMed ID: 12564662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
    Davies NM; McLachlan AJ; Day RO; Williams KM
    Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.
    Hynninen VV; Olkkola KT; Neuvonen PJ; Laine K
    Eur J Clin Pharmacol; 2009 Jan; 65(1):89-95. PubMed ID: 18777173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and structural characterization of the photolysis products of etoricoxib.
    Matthews CZ; Subramanian R; Woolf EJ; Foster N; Matuszewski BK
    Pharmazie; 2004 Dec; 59(12):913-9. PubMed ID: 15638077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.